Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Renal Cancer Treatment

  • Philippe PaparelEmail author
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_6325-3


Renal cancer accounts for 2–3 % of all cancers. Clear-cell carcinoma is the most common anatomopathological form. The widespread prescription of radiological examination (US exam or CT scan) has led to an increase in the discovery of small and usually asymptomatic tumors. The therapeutic care of renal cancers differs depending on whether the tumor is localized or metastatic.


Treatment of Localized Renal Cancer

Surgical Treatment

The reference treatment for localized renal cancer is still surgical. It consists of either an extended nephrectomy (ablation of the kidney together with the adrenal gland and perirenal fat) or nephron-sparing surgery (tumorectomy or partial nephrectomy). Cortical tumors smaller than 40 mm should in theory receive nephron-sparing surgery especially if the patient suffers from renal insufficiency or has only one kidney. Furthermore, some genetic diseases such as von Hippel-Lindau diseasehave a high incidence of bilateral and...


Radiofrequency Ablation Renal Cancer Cytoreduction Nephrectomy Cortical Tumor Urinary Fistula 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell carcinoma. N Engl J Med 345:1655–1659CrossRefPubMedGoogle Scholar
  2. Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PFA, Patard JJ, Sinescu IC (2007) Renal cell carcinoma. EAU Guidelines. pp 1–28Google Scholar
  3. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358:966–970CrossRefPubMedGoogle Scholar
  4. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16–24CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of UrologyLyon Sud University HospitalPierre BeniteFrance